R (Bayer and Novartis) v NHS Darlington Clinical Commissioning Groups

In March, the Court of Appeal handed down judgment in a highly significant case for the NHS which will have widespread effects on the NHS' ability to deliver clinically- and cost-effective medicine. The NHS bodies' success in this case should assist the NHS to make more informed rational and cost-effective decisions in its delivery of care within a fixed budget.

David Lock QC and David Blundell QC acted for the successful NHS bodies in R (Bayer and Novartis) v NHS Darlington Clinical Commissioning Groups and others, explain the background, arguments and consequences of the case.

Contents

Introduction:(0:00)

Transcript

Part 1: The Legal and Regulatory Background (5:59)

Transcript

Part 2: An explanation of the background to the treatment of wet AMD patients within the NHS (20:55)

Transcript

Part 3: Details of the policy adopted by the CCGs (33:18)

Transcript

Part 4: The grounds of challenge and the lines of defence (42:26)

Transcript

Part 5: The judgment of the Court of Appeal (52:26)

Transcript

Part 6: What happens next and the consequences for the NHS (1:06:41)

Transcript